Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL
Wayne Kuznar
Read More
Rituximab Maintenance and Radioimmunotherapy Are Cost-Effective After First-Line Therapy in Follicular Lymphoma
Wayne Kuznar
Read More
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
Wayne Kuznar
Read More
Leukemia
Idelalisib Improves Outcomes in Heavily Pretreated Patients with CLL
Wayne Kuznar
Read More
Drug Updates
Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Lisa A. Raedler, PhD, RPh
Read More
Conference Highlights ASH
Siltuximab: Monoclonal Antibody Relieves Symptoms of Castleman’s Disease
Read More
Conference Highlights ASH
More Transplants Made Possible Through Haploidentical Donors
Caroline Helwick
Read More
Conference Highlights ASH
Hospital Readmission After Stem-Cell Transplant Decreases Survival
Wayne Kuznar
Read More
Conference Highlights ASH
JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis
Wayne Kuznar
Read More
Payers' Perspectives
Increasing Emphasis on Costs in the Management of Patients with Hematologic Cancers
Matthew Mitchell, PharmD, MBA, FAMCP
Read More
1
2
3
4
Page 1 of 4
Results 1 - 10 of 32